Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
about
Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimerOn the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporineSelectivity of docking sites in MAPK kinasesComparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi.Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein PhosphatasesDrugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birthMitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Role of ERK/MAPK in endothelin receptor signaling in human aortic smooth muscle cells.Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease.Toward transcriptional therapies for the failing heart: chemical screens to modulate genesSensitivity analysis predicts that the ERK-pMEK interaction regulates ERK nuclear translocation.PKC δ and βII regulate angiotensin II-mediated fibrosis through p38: a mechanism of RV fibrosis in pulmonary hypertension.Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy optionsEfficient PKC inhibitor screening achieved using a quantitative CE-LIF assay.Cell signalling in the cardiovascular system: an overview.Stroke prevention: managing modifiable risk factors.Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease.Novel host response therapeutic approaches to treat periodontal diseases.Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging.Systems biology analysis of G protein and MAP kinase signaling in yeast.Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiationHypoxia-induced signaling in the cardiovascular system.Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.4-methylcoumarin derivatives inhibit human neutrophil oxidative metabolism and elastase activity.The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophyThe potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failurePhosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stageOxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemiaJNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.Quantitative proteomic and phosphoproteomic analysis of Trypanosoma cruzi amastigogenesis.Discovery of Rho-kinase inhibitors by docking-based virtual screening.Daunorubicin induces cell death via activation of apoptotic signalling pathway and inactivation of survival pathway in muscle-derived stem cells.Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts.Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.The new revolution in toxicology: the good, the bad, and the ugly.The effect of an adenosine and lidocaine intravenous infusion on myocardial high-energy phosphates and pH during regional ischemia in the rat model in vivo.
P2860
Q24294617-5108C3F2-5EFB-467C-B0BE-F6DE27717769Q24642110-83617789-BBF5-48B5-B3F9-185978CF954AQ24651580-F7052E89-6CDC-4DB7-94C4-AF142F28BAEBQ24815881-99BD5486-0F75-41AD-8B8C-166E63CC717CQ26776182-7FB69805-4040-4FB3-A580-DDE714F64BA7Q28081049-7FEEC2BE-8151-4B50-A0DF-2F00C25D8B7EQ28296128-0A6DF3CC-C0C5-408D-8772-C8C4682FFCA3Q33477974-4F829888-B085-4FBA-A78C-FB0F57382886Q33604010-C952BF07-135D-455E-B36A-817A010D6F8FQ33683749-AA1A7D9D-9212-40F1-B087-747435E31803Q34989366-5AF7D6D0-9BA7-461C-A6EB-BF80E05925A0Q35437493-5223CBE2-D900-4B3A-B325-7070F235F3AEQ35818209-F0605C99-426A-4E9C-ADD6-111F8BD0C9E8Q36174816-27665860-FFCD-4032-BD07-5F6E1A2B380FQ36257377-3973EC27-272C-440F-B154-4FFE257B33BDQ36418118-E0F43794-A21C-4C3F-BB55-D0D91A1A30D2Q36549642-FEF4F731-B309-4507-BC5E-3459290EFD24Q36703987-4BCE2EB3-060E-4E10-93C7-22D2A43A65C0Q36761505-B596E63E-9D77-4CDD-A1A1-34D26861ED18Q36802178-61B01618-6F37-4916-A0F6-3F7A17B85635Q36819405-737F82B9-5709-4180-A1FB-8AF7D98C62C2Q36891571-D471ADC9-C686-4F94-9E85-39229B828EA3Q36938391-21135261-254D-4E5B-8D97-56B419267B13Q37097105-A25359FC-E8AD-46FE-8633-E7838DA1900BQ37115064-FE4C2E9F-E8DD-4EBF-AFDE-22B257FA64DFQ37264079-6A44D1C3-C076-4AA2-998F-279D2F7196CEQ37361567-EADB9B34-C86A-4B9C-93EE-8A867DDD433CQ37364454-79F491DE-BF7B-472C-8F6D-11971C65196AQ37716059-17CFBFED-0BA9-4248-9C24-BD896E8F4733Q37793978-F3B84087-2C9E-4EB1-AFCB-F0A29461DB59Q38974348-A79752D0-AE10-4D12-8FF0-BE22DCB16D16Q39128436-88B742AC-EE97-42F7-A726-2D76626B9B2FQ39172399-7E97D1A2-AD6C-4AA1-BCF7-2DFF0E1DF32AQ39410853-83384D3B-D4BC-4F1D-82BB-37E035BDEF65Q40341746-0A02AFEC-1C42-49E0-BD21-0570E4C735A0Q40460320-9EDB8BD0-A134-4883-B7EB-0DF4F673B1BAQ41807552-3BFD7CD7-0986-4F55-9578-E0E5CF8C5583Q42058629-394C17AD-3689-448B-904E-0ADB11006A05Q45421942-D4670294-DF27-44A9-8927-9FC54A82C0A4Q48643177-699EE6D2-BA2A-4CD3-8DE1-085446800BF2
P2860
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@ast
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@en
type
label
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@ast
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@en
prefLabel
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@ast
Inhibitors of protein kinase s ...... es for cardiovascular disease.
@en
P2093
P1433
P1476
Inhibitors of protein kinase s ...... ies for cardiovascular disease
@en
P2093
John M Kyriakis
Keisuke Kuida
Keykavous Parang
Mark Namchuk
P304
P356
10.1161/01.CIR.0000118538.21306.A9
P407
P50
P577
2004-03-01T00:00:00Z